Capital International Investors
ABCL icon

Capital International Investors’s AbCellera Biologics ABCL Stock Holding History

Capital International Investors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,626,644
Closed -$25.6M – 437
2022
Q1 		$25.6M Sell
2,626,644
-5,505,307
-68% -$52.1M 0.01% 391
2021
Q4 		$116M Buy
8,131,951
+1,022,062
+14% +$15.5M 0.02% 306
2021
Q3 		$142M Buy
7,109,889
+215,800
+3% +$3.81M 0.03% 274
2021
Q2 		$152M Buy
6,894,089
+5,097,178
+284% +$141M 0.03% 266
2021
Q1 		$61M Buy
1,796,911
+1,046,911
+140% +$41.7M 0.02% 327
2020
Q4 		$30.2M Buy
+750,000
New +$34.3M 0.01% 368

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GCAC
Guardian Capital Advisors (Canada) Toronto, Ontario, Canada $1.02B AUM 25.29% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Capital International Investors's ABCL Position: Q2 2022 in Review

Capital International Investors sold out of AbCellera Biologics (ABCL) in Q2 2022, closing a stake of 2,626,644 shares — an estimated $25.6M sold.

Capital International Investors first reported a position in ABCL in Q4 2020 and held it in 6 quarters. The position peaked at $152M in Q2 2021. 161 funds tracked by Wall St. Rank hold ABCL as of Q2 2022.

  • Capital International Investors reported no remaining AbCellera Biologics position as of Q2 2022 after selling out during the quarter.
  • Capital International Investors sold 2,626,644 AbCellera Biologics shares in Q2 2022, an estimated $25.6M.
  • Capital International Investors first reported a position in AbCellera Biologics in Q4 2020 and held it in 6 quarters.
  • Capital International Investors's AbCellera Biologics position peaked at $152M in Q2 2021.
  • 161 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2022.

Based on Capital International Investors's 13F filing for Q2 2022, filed 15 Aug 2022.